| 1.76 0.15 (9.32%) | 04-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.19  |
1-year : | 2.44 |
| Resists | First : | 1.87 |
Second : | 2.08 |
| Pivot price | 1.67 |
|||
| Supports | First : | 1.53 | Second : | 1.27 |
| MAs | MA(5) : | 1.64 |
MA(20) : | 1.71 |
| MA(100) : | 2.22 |
MA(250) : | 2.36 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 34.2 |
D(3) : | 16.2 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 4.98 | Low : | 1.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FLNA ] has closed below upper band by 12.2%. Bollinger Bands are 65.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.77 - 1.78 | 1.78 - 1.79 |
| Low: | 1.56 - 1.57 | 1.57 - 1.58 |
| Close: | 1.74 - 1.76 | 1.76 - 1.77 |
Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
Wed, 15 Apr 2026
In severe epilepsy mouse model, Filana drug slowed seizure worsening - Stock Titan
Tue, 14 Apr 2026
FLNA Options Chain — NASDAQ:FLNA - TradingView — Track All Markets
Mon, 13 Apr 2026
FLNA Options Volatility — NASDAQ:FLNA - TradingView — Track All Markets
Thu, 26 Mar 2026
Filana Therapeutics, Inc. Balance Sheet – NASDAQ:FLNA - TradingView — Track All Markets
Fri, 13 Mar 2026
FLNA Price Today: Filana Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 12.7 (%) |
| Held by Institutions | 28.9 (%) |
| Shares Short | 7,320 (K) |
| Shares Short P.Month | 7,090 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.3 % |
| Return on Equity (ttm) | -82.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.56 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | 20 (M) |
| PE Ratio | -0.94 |
| PEG Ratio | 0 |
| Price to Book value | 1.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.64 |
| Dividend | 5.25 |
| Forward Dividend | 0 |
| Dividend Yield | 298.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|